Drugs / Trifluridine/tipiracil
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07381764 Comparator | Mar 2026 → Mar 2031 expected | colorectal cancer | Gruppo Oncologico Italia Meridionale | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07381764 ↗ |
| Route | Oral | “is an oral antineoplastic combination” NCT07381764 ↗ |